Tandem Diabetes Care Announces Issuance of Patent Related to Important Safety Features for Portable Infusion Pumps that Utili...
August 08 2017 - 7:30AM
Business Wire
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device
company and manufacturer of the only touchscreen insulin pumps
available in the United States, today announced the issuance of
U.S. Patent No. 9,715,327 titled “Preventing Inadvertent Changes in
Ambulatory Medical Devices”. The patent relates to important safety
features for the prevention of inadvertent changes in touchscreen
enabled ambulatory infusion pumps, including insulin pumps. The
touchscreen may be on the pump itself or be in wireless
communication with a pump.
“We are the first and only company to receive FDA approval of an
insulin pump with a touchscreen. This patent significantly
strengthens our intellectual property position surrounding Tandem’s
user interface and the implementation of important features in
other ambulatory infusion pumps that utilize touchscreen control,”
said Kim Blickenstaff, President and Chief Executive Officer of
Tandem Diabetes Care. “This new patent validates the novel
solutions we developed to give users the security of operating a
life-sustaining medical device using a touchscreen and protects the
creative solutions developed at Tandem.”
The user interface for the t:slim, t:slim X2, t:flex and t:slim
G4 Insulin Pumps were developed based on information and feedback
collected from thousands of interviews, focus groups and online
surveys to understand what people with diabetes, their caregivers
and healthcare providers wanted in order to improve diabetes
therapy management. The Company also utilized human factors
research in its development process so that users can more
successfully operate their insulin pump in its intended
environment.
U.S. Patent No. 9,715,327 is scheduled to expire in 2033. The
Company has a related U.S. continuation application on file, as
well as a pending application in Europe.
Tandem Diabetes Care now has 55 issued U.S. patents and 51
pending U.S. patent applications. In addition, the Company has, and
is seeking, patent protection for proprietary technologies in other
countries throughout the world.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical
device company with an innovative, user-centric and integrated
approach to the design, development and commercialization of
products for people with diabetes who use insulin. The Company
manufactures and sells the t:slim X2™ Insulin Pump, the slimmest
and smallest durable insulin pump currently on the market, the
t:flex® Insulin Pump, the first pump designed for people with
greater insulin requirements, and the t:slim G4™ Insulin Pump, the
first continuous glucose monitoring-enabled pump with touch-screen
simplicity. Tandem is based in San Diego, California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use
#tslimX2, #tslimG4, #tflex, #tconnect, and $TNDM.Follow Tandem
Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.Follow
Tandem Diabetes Care on LinkedIn at
https://www.linkedin.com/company/tandemdiabetes.
Tandem Diabetes Care, t:connect and t:flex are registered
trademarks, and t:slim X2 and t:slim G4 are trademarks of Tandem
Diabetes Care, Inc. All other trademarks are the property of their
respective owners.
Forward Looking Statement
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, that concern matters that involve risks and uncertainties
that could cause actual results to differ materially from those
anticipated or projected in the forward-looking statements. These
forward-looking statements relate to, among other things the scope
and enforceability of the company’s intellectual property,
including the expected expiration of the 9,715,327 patent. Many
factors could cause the company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements, including without limitation,
those listed under the heading “Risk Factors” in the company’s most
recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q
and other documents that Tandem files with the Securities and
Exchange Commission. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this release. Tandem undertakes no obligation to
update or review any forward-looking statement in this press
release because of new information, future events or other
factors.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170808005337/en/
Tandem Diabetes Care, Inc.Media Contact:Steve Sabicer,
714-907-6264ssabicer@thesabicergroup.comorInvestor
Contact:Susan Morrison,858-366-6900
x7005smorrison@tandemdiabetes.com
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Apr 2024 to May 2024
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From May 2023 to May 2024